{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:35:51Z","timestamp":1791423351935,"version":"4.3.3"},"reference-count":64,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the literature concerning the in vitro activity, pharmacokinetic properties, in vivo efficacy, and adverse events associated with a new penem antibiotic, faropenem medoxomil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>We conducted a search of MEDLINE\/PubMed and International Pharmaceutical Abstracts databases for articles or abstracts using the terms faropenem. faropenem daloxate, faropenem medoxomil, SUN5555, SY5555, WY49605, RU67655, ALP201. BLA857, and YM044 and published through July 2007. Information on poster presentations was obtained from the drug's manufacturer. Additional articles were identified from citations in the bibliographies of review articles. Articles written in languages other than English were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All published reports that evaluated faropenem (or its chemical synonyms) and faropenem medoxomil were used in this review. Abstracts subsequently published as full reports were excluded, and only the resulting reports were included. Abstracts without subsequently published reports were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The in vitro activity of faropenem has been evaluated extensively against respiratory pathogens and less extensively against aerobic gram-positive, gram-negative, and anaerobic organisms. Prospective, randomized, multicenter clinical trials have demonstrated noninferiority of faropenem to comparators for the treatment of acute bacterial sinusitis, community-acquired pneumonia, acute exacerbation of chronic bronchitis, and uncomplicated skin and skin structure Infections. Adverse events associated with faropenem appear to be minimal and include nausea, vomiting, and diarrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Faropenem has demonstrated excellent in vitro activity against common respiratory pathogens, many aerobic gram-positive organisms, and anaerobes. Activity against gram-negative organisms is more reserved. In vivo data suggest that faropenem is efficacious in treating community-acquired Infections Including uncomplicated skin and skin structure infections; however, more data may help to characterize faropenem's place in antimicrobial therapy. Replidyne, Inc., the manufacturer of faropenem, is conducting studies to address the Food and Drug Administration's concerns that resulted in a nonapprovable letter in October 2006.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g232","type":"journal-article","created":{"date-parts":[[2007,12,19]],"date-time":"2007-12-19T21:06:08Z","timestamp":1198098368000},"page":"80-90","source":"Crossref","is-referenced-by-count":30,"title":["Faropenem Medoxomil"],"prefix":"10.1177","volume":"42","author":[{"given":"Jacob P","family":"Gettig","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W","family":"Crank","sequence":"additional","affiliation":[{"name":"Clinical Specialist, Infectious Diseases, Department of Pharmacy, Rush University Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H","family":"Philbrick","sequence":"additional","affiliation":[{"name":"Pharmacy Manager, Dominicks Pharmacy, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,12,4]]},"reference":[{"key":"bibr1-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1159\/000070616"},{"key":"bibr2-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.14.1497.31937"},{"key":"bibr3-aph.1G232","unstructured":"ChambersH. Penicillins. In: MandellG, BennettJE, DolinR, eds. Principles and practice of infectious diseases. Vol 1. Philadelphia: Elsevier, 2005:281\u201393."},{"key":"bibr4-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1159\/000071141"},{"key":"bibr5-aph.1G232","author":"Voith B","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr6-aph.1G232","author":"Voith B","year":"2000","journal-title":"Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr7-aph.1G232","author":"Letterieri JT","year":"2000","journal-title":"Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr8-aph.1G232","author":"van den Ankler J","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"bibr9-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf155"},{"key":"bibr10-aph.1G232","author":"Craig WA","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr11-aph.1G232","first-page":"245","volume":"18","author":"Tsuji A","year":"1990","journal-title":"Drug Metab Dispos"},{"key":"bibr12-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00977.x"},{"key":"bibr13-aph.1G232","author":"Schmidt A","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr14-aph.1G232","author":"Schuehly U","year":"2000","journal-title":"Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr15-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.574-577.2000"},{"key":"bibr16-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.2407"},{"key":"bibr17-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2002.027.03.659134"},{"key":"bibr18-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.3.415"},{"key":"bibr19-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg263"},{"key":"bibr20-aph.1G232","author":"Schmidt A","year":"2000","journal-title":"Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr21-aph.1G232","author":"Khunvichai A","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr22-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.1.23"},{"key":"bibr23-aph.1G232","author":"Young CL","year":"2006","journal-title":"Clin Microb Infect"},{"key":"bibr24-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.4.686-707.2000"},{"key":"bibr25-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf139"},{"key":"bibr26-aph.1G232","author":"Kresken M","year":"2002","journal-title":"Presented at: 12th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"bibr27-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.203-207.2001"},{"key":"bibr28-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.1.35"},{"key":"bibr29-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf100"},{"key":"bibr30-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf098"},{"key":"bibr31-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.8.2010"},{"key":"bibr32-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1591"},{"key":"bibr33-aph.1G232","author":"Fuchs PC","year":"1994","journal-title":"Presented at: 34th Interscience Conference of Antimicrobial Agents and Chemotherapy"},{"key":"bibr34-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00049-9"},{"key":"bibr35-aph.1G232","author":"Dorai-John T","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr36-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1999.tb00142.x"},{"key":"bibr37-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_3.5"},{"key":"bibr38-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-003-0990-7"},{"key":"bibr39-aph.1G232","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/49.3.573","volume":"49","author":"duPlessis M","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"bibr40-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.550-555.2002"},{"key":"bibr41-aph.1G232","author":"Black JA","year":"2001","journal-title":"Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr42-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg120"},{"key":"bibr43-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.201.157"},{"key":"bibr44-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3669-3675.2002"},{"key":"bibr45-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/49.1.220"},{"key":"bibr46-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2003.15.6.525"},{"key":"bibr47-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1211"},{"key":"bibr48-aph.1G232","author":"Bauerfeind A","year":"2000","journal-title":"Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr49-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00283-8"},{"key":"bibr50-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1159\/000072446"},{"key":"bibr51-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.7.1964-1971.2001"},{"key":"bibr52-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-002-0176-8"},{"key":"bibr53-aph.1G232","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.44.266"},{"key":"bibr54-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2001.tb00038.x"},{"key":"bibr55-aph.1G232","first-page":"645","volume":"52","author":"Togawa J","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"bibr56-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-002-0532-4"},{"key":"bibr57-aph.1G232","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.05.034"},{"key":"bibr58-aph.1G232","author":"Kowalsky S","year":"2005","journal-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr59-aph.1G232","author":"Walker G","year":"2005","journal-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr60-aph.1G232","author":"Corrado M","year":"2005","journal-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr61-aph.1G232","author":"Corrado M","year":"2005","journal-title":"Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"key":"bibr62-aph.1G232","author":"Echols R","year":"2006","journal-title":"Presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases"},{"key":"bibr63-aph.1G232","unstructured":"Replidyne, Inc.; Forest Laboratories, Inc. U.S. Food and Drug Administration issues non-approvable letter for faropenem. Louisville, CO: Replidyne, Inc.; 2006 Oct. http:\/\/ir.eplidyne.com\/phoenix.zhtml?c=189384&p=irol-newsArticle&ID=919447&highlight= (accessed 2007 Jul 20)."},{"key":"bibr64-aph.1G232","unstructured":"Replidyne, Inc. Replidyne and Forest End Faropenem Collaboration. Louisville, CO: Replidyne, Inc.; 2007 Feb. http\/\/ir.replidyne.com\/phoenix.zhtml?c=189384&p=irol-newsArticle&ID=959597&highlight= (accessed 2007 Jul 20)."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G232","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:40Z","timestamp":1777374580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1345\/aph.1G232"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g232","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}